886498-99-3

Usage

Uses

Used in Organic Synthesis:
3-Fluoro-4-(trifluoromethoxy)benzyl alcohol is used as a building block for the preparation of various pharmaceuticals and agrochemicals. Its unique chemical structure allows it to be a versatile component in the synthesis of complex organic molecules.
Used in Chemical Reactions:
3-Fluoro-4-(trifluoromethoxy)benzyl alcohol is used as a reagent in chemical reactions. Its presence can facilitate or enhance the reaction process, leading to the desired products with improved efficiency and selectivity.
Used as a Solvent:
3-Fluoro-4-(trifluoromethoxy)benzyl alcohol is used as a solvent in organic synthesis. Its ability to dissolve a wide range of organic compounds makes it a valuable asset in various chemical processes.
Used in the Development of New Materials:
3-Fluoro-4-(trifluoromethoxy)benzyl alcohol has potential applications in the development of new materials due to its unique chemical structure and properties. It can be incorporated into the design and synthesis of advanced materials with specific functions and characteristics.
Used in Pharmaceutical Development:
3-Fluoro-4-(trifluoromethoxy)benzyl alcohol is used in the development of new pharmaceuticals. Its unique chemical structure can be exploited to create novel drug candidates with improved therapeutic properties and reduced side effects.

InChI:InChI=1/C8H6F4O2/c9-6-3-5(4-13)1-2-7(6)14-8(10,11)12/h1-3,13H,4H2

Upstream product

• 1197231-80-3 ethyl 3-fluoro-4-(trifluoromethoxy)benzoate 
• 886498-89-1 3-fluoro-4-(trifluoromethoxy)benzoic acid 
• 473917-15-6 3-fluoro-4-(trifluoromethoxy)benzaldehyde 

Downstream Products

• 1400698-58-9 sodium 4-{[[3-fluoro-4-(trifluoromethoxy)benzyl](4-methylisoquinolin-3-yl)-amino]sulfonyl}benzoate 
• 1321963-41-0 (S)-6-(3-fluoro-4-(trifluoromethoxy)benzyloxy)-2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine 
• 886499-04-3 4-(bromomethyl)-2-fluoro-1-(trifluoromethoxy)benzene 

Relevant academic research and scientific papers

TRIAZOLE COMPOUNDS AS T-TYPE CALCIUM CHANNEL BLOCKERS

The invention relates to compounds of formula (I) wherein X, Y, R1, R2, (R4)n, and (R5)m are as defined in the description, and to pharmaceutically acceptable salts of such compounds. These compounds are useful as calcium T-channel blockers.

SULFONAMIDE COMPOUNDS HAVING TRPM8 ANTAGONISTIC ACTIVITY

Sulfonamide compounds having TRPM8 antagonistic activity are provided. A sulfonamide compound of formula (I) or a pharmaceutically acceptable salt thereof, or a prodrug thereof: (I) wherein Ring A is bicyclic aromatic heterocycle comprised of (a) pyridine is condensed with benzene; or (b) pyridine is condensed with monocyclic aromatic heterocycle, and Ring A binds to a sulfonylamino moiety on a carbon atom adjacent to a nitrogen atom of the pyridine ring constituting Ring A, Ring B is (a) monocyclic or bicyclic aromatic hydrocarbon; (b) monocyclic or bicyclic alicyclic hydrocarbon; (c) monocyclic or bicyclic aromatic heterocycle; or (d) monocyclic or bicyclic non-aromatic heterocycle, Ring C is (a) benzene; or (b) monocyclic aromatic heterocycle, and other symbols are the same as defined in the specification.

Structure-activity relationships of antitubercular nitroimidazoles. 3. Exploration of the linker and lipophilic tail of ((S)-2-nitro-6,7-dihydro-5 H -imidazo[2,1- b ][1,3]oxazin-6-yl)-(4-trifluoromethoxybenzyl)amine (6-amino PA-824)

The (S)-2-nitro-6-(4-(trifluoromethoxy)benzyloxy)-6,7-dihydro-5H-imidazo[2, 1-b][1,3]oxazine named PA-824 (1) has demonstrated antitubercular activity in vitro and in animal models and is currently in clinical trials. We synthesized derivatives at three positions of the 4-(trifluoromethoxy)benzylamino tail, and these were tested for whole-cell activity against both replicating and nonreplicating Mycobacterium tuberculosis (Mtb). In addition, we determined their kinetic parameters as substrates of the deazaflavin-dependent nitroreductase (Ddn) from Mtb that reductively activates these pro-drugs. These studies yielded multiple compounds with 40 nM aerobic whole cell activity and 1.6 μM anaerobic whole cell activity: 10-fold improvements over both characteristics from the parent molecule. Some of these compounds exhibited enhanced solubility with acceptable stability to microsomal and in vivo metabolism. Analysis of the conformational preferences of these analogues using quantum chemistry suggests a preference for a pseudoequatorial orientation of the linker and lipophilic tail.